Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $78.90 Average PT from Analysts

Oruka Therapeutics, Inc. (NASDAQ:ORKA) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $78.90.

Several equities analysts recently issued reports on the company. UBS Group lifted their price objective on Oruka Therapeutics from $50.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 16th. Wedbush raised their price target on Oruka Therapeutics from $45.00 to $85.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday. Finally, HC Wainwright boosted their price target on Oruka Therapeutics from $40.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, April 13th.

Oruka Therapeutics Stock Performance

Shares of ORKA stock opened at $69.68 on Thursday. The stock has a fifty day moving average price of $44.98 and a 200 day moving average price of $34.96. The stock has a market cap of $3.45 billion, a PE ratio of -37.46 and a beta of -0.54. Oruka Therapeutics has a 1 year low of $8.91 and a 1 year high of $70.50.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.16. As a group, equities research analysts predict that Oruka Therapeutics will post -2.25 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joana Goncalves sold 7,000 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $66.12, for a total value of $462,840.00. Following the sale, the insider directly owned 33,377 shares in the company, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 23,765 shares of company stock worth $1,089,745. Corporate insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada boosted its stake in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after acquiring an additional 420 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after acquiring an additional 788 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after purchasing an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in Oruka Therapeutics in the fourth quarter valued at $37,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.